Mirodenafil
Wikipedia on Answers.com:
Top
Mirodenafil
 |
|
|---|---|
| Systematic (IUPAC) name | |
| 5-Ethyl-3,5-dihydro-2-[5-([4-(2-hydroxyethyl)-1-piperazinyl]sulfonyl)-2-propoxyphenyl]-7-propyl-4H-pyrrolo[3,2-d]pyrimidin-4-one | |
| Clinical data | |
| Pregnancy cat. | ? |
| Legal status | Unscheduled |
| Identifiers | |
| CAS number | 862189-95-5  |
| ATC code | ? |
| PubChem | CID 12001014 |
| UNII | 504G362H0H |
| Chemical data | |
| Formula | C26H37N5O5S |
| Mol. mass | 531.666 g/mol |
| SMILES | eMolecules & PubChem |
 (what is this?) (verify) |
|
Mirodenafil belongs to a class of drugs called PDE5 inhibitors, which many other erectile dysfunction drugs such as sildenafil, tadalafil, and vardenafil also belong to. It was developed by SK Chemicals Life Science Biz.and is marketed under the trade name of Mvix tab which comes in different doses(50mg,100mg).
Mirodenafil is also available under the name of Mvix S ODF 50mg as an Orally dissolving film(ODF) which dissolves on the tongue without water. It is the first licensed medicine for the treatment of Erectile Dysfunction as a dosage form of film.
It is not currently approved for use in the United States by the U.S. Food and Drug Administration, but clinical trials are being conducted.[1][2][3]
References
- ^ Paick JS, Ahn TY, Choi HK, Chung WS, Kim JJ, Kim SC, Kim SW, Lee SW, Min KS, Moon KH, Park JK, Park K, Park NC, Suh JK, Yang DY, Jung HG (November 2008). "Efficacy and safety of mirodenafil, a new oral phosphodiesterase type 5 inhibitor, for treatment of erectile dysfunction". The Journal of Sexual Medicine 5 (11): 2672–80. doi:10.1111/j.1743-6109.2008.00945.x. PMID 18638004.
- ^ Kim BH, Yi S, Kim J, Lim KS, Kim KP, Lee B, Shin SG, Jang IJ, Yu KS (June 2009). "Influence of alcohol on the hemodynamic effects and pharmacokinetic properties of mirodenafil: a single-dose, randomized-sequence, open-label, crossover study in healthy male volunteers in Korea". Clinical Therapeutics 31 (6): 1234–43. doi:10.1016/j.clinthera.2009.06.008. PMID 19695390.
- ^ Shin KH, Kim BH, Kim TE, Kim JW, Yi S, Yoon SH, Cho JY, Shin SG, Jang IJ, Yu KS (December 2009). "The effects of ketoconazole and rifampicin on the pharmacokinetics of mirodenafil in healthy Korean male volunteers: an open-label, one-sequence, three-period, three-treatment crossover study". Clinical Therapeutics 31 (12): 3009–20. doi:10.1016/j.clinthera.2009.12.012. PMID 20110038.
|
||||||||||||||||
|
||||||||||||||||||||||||||||||||
 |
This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by expanding it. |
This entry is from Wikipedia, the leading user-contributed encyclopedia. It may not have been reviewed by professional editors (see full disclaimer)
Related Videos:
Top
Mirodenafil
Post a question - any question - to the WikiAnswers community:
Copyrights:
Wikipedia on Answers.com
This article is licensed under the Creative Commons Attribution/Share-Alike License. It uses material from the Wikipedia article Mirodenafil.
Read more